Evidence map›Paper›PMID 28186998›Full record

ArticleOncotarget2017

Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.

Tamara L Lotan, Alba Torres, Miao Zhang, Jeffrey J Tosoian, Liana B Guedes, Helen Fedor, Jessica Hicks, Charles M Ewing, Sarah D Isaacs, Dorhyun Johng and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Genomic and Clinicopathologic Characterization ofClinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Tamara L LotanDepartments of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alba TorresDepartments of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Miao ZhangDepartments of Pathology, MD Anderson Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jeffrey J TosoianDepartments of Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Liana B GuedesDepartments of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Helen FedorDepartments of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jessica HicksDepartments of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Charles M EwingDepartments of Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sarah D IsaacsDepartments of Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dorhyun JohngDepartments of Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Angelo M De MarzoDepartments of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William B IsaacsDepartments of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USJohns Hopkins University · USThe University of Texas MD Anderson Cancer Center · US

Funding

TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
NCI NIH HHS P50 CA058236
6 · The paper itself

Abstract

A recurrent germline mutation (G84E) in the HOXB13 gene is associated with early onset and family history-positive prostate cancer in patients of European descent, occurring in up to 5% of prostate cancer families. To date, the molecular features of prostate tumors occurring in HOXB13 G84E carriers have not been studied in a large cohort of patients. We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls. Immunostaining for HOXB13, PTEN, ERG, p53 and SPINK1 as well as RNA in situ hybridization for ETV1/4/5 were performed using genetically validated assays. Tumors from G84E carriers generally expressed HOXB13 protein at a level comparable to benign and wild-type glands. ETS gene expression (either ERG or ETV1/4/5) was seen in 36% (36/101) of tumors from G84E carriers compared to 68% (65/96) of the controls (p < 0.0001). PTEN was lost in 11% (11/101) of G84E carriers compared to 25% (25/99) of the controls (p = 0.014). PTEN loss was enriched among ERG-positive compared to ERG-negative tumors in both groups of patients. Nuclear accumulation of the p53 protein, indicative of underlying TP53 missense mutations, was uncommon in both groups, occurring in 1% (1/101) of the G84E carriers versus 2% (2/92) of the controls (p = NS). Taken together, these data suggest that genes other than ERG and PTEN may drive carcinogenesis/progression in the majority of men with germline HOXB13 mutations.

Indexed as

Biomarkers, TumorCase-Control StudiesFollow-Up StudiesGenetic Predisposition to DiseaseGenotypeGerm-Line MutationHomeodomain ProteinsHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProstatic NeoplasmsRisk FactorsBiomarkers, TumorHomeodomain ProteinsHOXB13 protein, humanERGfamilial prostate cancerHOXB13 G84Eprostatic adenocarcinomaPTEN

Identifiers

PMID28186998
PMCPMC5410261
OpenAlexW2588340323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.